Generative AI is transforming pharmaceutical RÝ into a highly efficient, end-to-end new era. Insilico Medicine has accumulated extensive experience in AI-driven drug discovery, sharing breakthroughs and latest advancements in molecular design, multi-target synergy, and clinical translation success rates.
Insilico Medicine announces a $2.5 billion global R&D collaboration with SK Biopharmaceuticals to discover AI-enabled drug candidates for neuroimmune disorders. The company's Pharma.AI platform will drive target-to-candidate discovery, while SK Biopharmaceuticals will handle late-stage clinical development and commercialization.
Insilico Medicine announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals, focusing on neuroimmune disorders. The company showcased its proprietary Pharma.AI platform and demonstrated its expertise in accelerating drug discovery.
Insilico and SK Biopharmaceuticals collaborate on AI-powered drug discovery for neuroimmune disorders, aiming to accelerate discovery timelines and advance next-generation therapies. The partnership could be worth up to $2.5 billion, with Insilico receiving upfront and milestone payments.
Insilico Medicine will showcase its core capabilities and latest R&D pipeline at the BIO 2026 International Convention. The company's CEO, Dr. Alex Zhavoronkov, will present four featured speeches on AI-driven drug discovery and quantum technology-enabled research.
Insilico Medicine has completed the first-in-human dosing of its AI-driven NLRP3 inhibitor ISM8969 in a Phase I clinical study. The trial aims to evaluate the safety, tolerability, and efficacy of ISM8969 in healthy participants and those at risk of cardiovascular disease.
Insilico Medicine has completed the first-in-human dosing of its AI-driven NLRP3 inhibitor ISM8969 in a phase I clinical study. The trial achieved its first clinical milestone with partner Hygtia Therapeutics, evaluating the safety and efficacy of the treatment for chronic neuroinflammation.
Insilico Medicine is revolutionizing preclinical drug development through its AI and automation platform, reaching PCC nomination in just 12-18 months. The company has nominated 31 PCCs since 2021, with 13 receiving IND approval or clearance.
Alex Zhavoronkov, founder of Insilico Medicine, has been named to the inaugural SCW75 list for his work in AI-driven drug discovery and longevity research. The company's Pharma.AI platform has drastically compressed traditional drug discovery timelines, advancing 30 developmental candidates to clinical trials.
Jue Wang joins Insilico Medicine as Global Head of Business Development to drive high-value alliances and empower commercial growth. She brings expertise in small-molecule novel drug discovery and has led landmark collaborations worth USD 4 billion.
Insilico Medicine will present its end-to-end Pharma.AI platform and latest pipeline, highlighting the synergy between AI-driven drug design, quantum algorithms, and automation labs. The company has built an extensive therapeutic portfolio across various areas and rapidly advancing its internal R&D pipeline.
The collaboration aims to jointly develop a super-intelligence AI foundation model to predict disease risk, diagnose conditions, and discover novel therapeutics. By integrating advanced algorithms with deep biological insights, the models are expected to drive breakthroughs in early detection and personalized interventions for age-rela...
Insilico Medicine's Pharma.AI platform combines with Ribo's expertise in oligonucleotide therapeutics, aiming to boost efficiency and certainty of clinical research. The partnership enables end-to-end empowerment of RNA interference and oligonucleotide therapeutics development.
LabClaw integrates PandaOmics, automated laboratory hardware matrix, LIMS, and multi-dimensional data analysis pipelines to create an end-to-end intelligent closed loop. The system features five types of agents and a Human-in-the-Loop confirmation mechanism for maximizing efficiency without compromising scientific safety standards.
The INS001-055 inhalation solution is the world's first AI-driven candidate to receive IND clearance. It targets Idiopathic Pulmonary Fibrosis (IPF) with a novel molecule structure and demonstrates good tolerability, PK profiles, and dose-dependent efficacy trend.
Insilico Medicine nominates UAE's first developmental preclinical candidate using generative AI, marking a significant step forward for pharmaceutical innovation. The milestone showcases the country's growing biotechnological capabilities and its rise as a global hub.
The review highlights key considerations for selecting an optimal drug target, including therapeutic hypothesis, druggability and safety, commercial tractability, and combination value. AI's capacity to process complex multimodal data enables researchers to navigate biological complexity and uncover disease-associated targets.
The Insilico Medicine Longevity Board aims to accelerate the development of therapeutics targeting the biological processes of aging. The board, led by Andrew Adams, will oversee AI-enabled aging research and drug discovery.
Insilico's unified AI framework combines disease-specific predictive modeling with rigorous benchmarking to improve target identification accuracy and reliability. The validated system generates actionable intelligence, prioritizing targets with strong potential for successful development.
Insilico Medicine has expanded its MMAI Gym platform, launching three benchmark leaderboard portals to evaluate AI systems in scientific research and drug discovery. The platforms assess broader scientific reasoning and end-to-end drug discovery tasks, enabling scalable evaluation of AI models.
The event showcases the Pharma.AI ecosystem's new capabilities, including the MMAI Gym for Science, updates to PandaOmics, Generative Biologics, and Chemistry42. Researchers can learn how to access these tools and best practices for tackling challenging problems in human health.
Researchers at Insilico Medicine have developed novel small molecular inhibitors and extremely selective PROTACs targeting the serine/threonine kinase PKMYT1. The discovery utilizes noncovalent interactions to achieve selectivity, masking hydrogen-bond donors that negatively affect permeability and solubility.
ISM6200 is a potent, potentially best-in-class preclinical candidate targeting NR3C1 for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol. The molecule demonstrates low DDI risks and higher in vivo efficacy across multiple animal models.
Researchers developed a compact AI model that reasons through chemistry logic, outperforming larger models on critical tasks. The Liquid Foundation Model achieves state-of-the-art success rates in molecular optimization and ADMET superiority.
Insilico Medicine will present four novel cancer inhibitors discovered via its Pharma.AI platform, targeting KRAS and Cbl-b pathways. ISM6166 and ISM3830 demonstrate robust anti-tumor activity against solid tumors with KRAS alterations and restored innate and adaptive immunity, respectively.
Insilico Medicine and Eli Lilly partner to accelerate discovery of novel therapeutics using AI engine, focusing on preclinical development for certain indications. The collaboration aims to deliver transformative therapies for diseases with high unmet need.
The companies are leveraging generative AI to develop innovative candidates for challenging neurological diseases, aiming to provide a broader range of therapeutic options. Insilico's Pharma.AI platform and Tenacia's expertise will continue to generate innovative solutions with strong translational potential.
Insilico Medicine recognized for demonstrating real-world clinical impact from its generative AI platform and achieving significant commercial milestones. The company's momentum is underscored by its successful public listing on the Hong Kong Stock Exchange.
The collaboration aims to identify therapeutic targets for challenging gynecological conditions using Insilico's AI-driven target identification engine, PandaOmics. ASKA will validate the AI-predicted targets with high translational potential, accelerating the development of innovative solutions for millions of patients worldwide.
PandaClaw automates complex real-time analyses, enabling researchers to discover novel targets and identify new indications through an intuitive natural language interface. The tool accelerates translational medical research by lowering the barrier for biologists to apply AI.
Insilico Medicine's inclusion in the Hang Seng Index and Stock Connect program is expected to enhance stock liquidity and market attention, strengthening the company's capital market influence. The company has achieved multiple drug development milestones, including 12 IND-enabling programs and preclinical candidates ISM0676 and ISM5059.
Insilico Medicine's Alex Zhavoronkov chairs precision aging discussion and presents Luminary Award to OpenAI president Greg Brockman. The company's AI-driven approaches accelerate drug discovery and advance precision medicine for aging and age-related diseases.
ISM4808, a PHD inhibitor for chronic kidney disease-related anemia, has achieved its first milestone with successful completion of the Phase I clinical trial. The treatment stimulates endogenous erythropoietin production and improves iron utilization, offering improved efficiency and safety compared to existing treatments.
The partnership produced a single checkpoint model, LFM2-2.6B-MMAI, that achieves state-of-the-art performance across multiple drug discovery subdomains and covers the complete discovery loop, including property prediction, molecular optimization, affinity prediction, chemical reasoning, and retrosynthesis planning.
Insilico's new platform automates business development workflows, increasing efficiency and quality of communication. The system integrates proprietary data with AI-powered interactions to streamline partner engagement and due diligence.
Researchers from Insilico Medicine and Lilly outline a comprehensive framework for fully autonomous, AI-orchestrated drug discovery. The vision integrates AI-driven target discovery, generative chemistry, automated synthesis, biological validation, and clinical planning into a single workflow.
The collaboration aims to uncover actionable targets and biological pathways that may lead to personalized therapeutic options and improved outcomes for patients. Insilico's PandaOmics platform integrates clinical datasets with AI models to systematically prioritize druggable targets.
The Harvard Business School case study explores the development of Insilico's lead asset, Rentosertib, which completed a Phase IIa clinical evaluation for idiopathic pulmonary fibrosis. Insilico Medicine has significantly improved preclinical drug development efficiency with its AI-driven approach.
Insilico Medicine and CMS announce multiple collaborations on AI-empowered drug discovery in central nervous system and autoimmune diseases. The partnerships aim to accelerate research, development, and translation of high-potential innovative therapies, leveraging complementary strengths across the entire value chain.
Halle Zhang joins Insilico Medicine to lead global clinical development strategy for the company's oncology portfolio. She brings over 20 years of experience in oncology clinical development and a track record of advancing therapies through registrational trials.
Insilico Medicine will present its latest AI-driven breakthroughs at WHX 2026, highlighting its role in accelerating translational research. The company's Abu Dhabi R&D center has established close collaborations with regional universities, driving innovation and generating global impact.
Insilico Medicine nominates ISM5059, a peripheral-restricted NLRP3 inhibitor, as a preclinical candidate for treating various inflammatory diseases. The compound has demonstrated high potency, selectivity, and excellent in vivo efficacy across animal disease models.
Insilico Medicine received a USD 5 million milestone payment from Menarini Group after completing first-in-human dosing in a Phase 1 study of MEN2501, a small molecule inhibitor targeting cancers with chromosome instability. This achievement follows the completion of a successful Phase 1 clinical trial.
ISM0676 demonstrates excellent metabolic stability, superior efficacy at low doses, and a favorable safety profile, leading to significant body weight reduction and improved body composition. The compound's synergistic efficacy with Semaglutide supports its further clinical development as an obesity treatment.
The collaboration aims to accelerate the development of small molecule inhibitors for treating metabolic diseases. Insilico will utilize its Pharma.AI platform to design and optimize novel molecules, while Qilu will handle subsequent development and commercialization.
Insilico Medicine has received investigational new drug (IND) clearance from the US FDA for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The Phase I clinical trial plans to evaluate the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers.
Science MMAI Gym trains LLMs in medicinal chemistry, biology, and clinical development with precision required in pharma R&D. Partner models emerge with up to 10x improvements in performance, matching state-of-the-art specialist models.
Insilico Medicine presents three abstracts at the 2026 Crohn's & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411. The first-in-human Phase 1 results show no serious adverse events or deaths reported, with a favorable pharmacokinetic profile supporting gut restriction.
The article highlights Insilico Medicine's exclusive contributions to two chapters in the latest AI for Drug Discovery Volume, showcasing its expertise in real-life application of AI in early drug target-related tasks. The company's roadmap to 2030 using Quantum Machine Learning (QML) algorithms is also presented, with successful case ...
The companies will jointly develop ISM8969, a brain penetrant NLRP3 inhibitor for treating neuroinflammation-related diseases. Preclinical data shows the molecule's efficacy and favorable safety profile.